Why is Ellume hitting headlines today?

Brisbane-based diagnostics developer Ellume is back in the headlines.

Rapid Antigen Test taking place.

Image source: Getty iMAGES

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Ellume is in the spotlight as the United States Government looks to buy another 500 million RATs
  • Additionally, the company has reportedly started working to get approval to sell its tests in Australia
  • There's still no word of Ellume listing on the ASX

Brisbane-based diagnostics developer Ellume is back in the headlines as demand for rapid antigen tests (RATs) continues to hit Australia and the world.

However – while there has been speculation – there's been no word as to whether we'll see shares in the company on our home-spun market.

Ellume isn't listed on the ASX. In fact, there's still nowhere for investors to publicly buy shares in the company.

Let's take a closer look at what's got many excited about the company this morning.

What's got ASX-watchers excited about Ellume on Friday?

The first news that might have put the spotlight on Ellume this morning came from its major market, the United States.

While most Australians slept last night, President Joe Biden announced that the United States Government will be handing out 1 billion free tests to citizens – 500 million more than previously promised. That means the government will be off to the shops looking to snap up the extra RATs.

Ellume's test was the first over the counter at-home RAT to be approved by the country's Food and Drug Administration back in December 2020. Since then, the United States Government has snapped up millions of them.

That likely leaves many wondering if its products could once again be in the government's cart.  

Back home, the ABC today reported it understands that Ellume has begun the journey of receiving Therapeutic Goods Administration (TGA) approval for its RAT tests.

If given the green light by the regulator, the tests will be allowed to be purchased by Australian consumers. Though, that doesn't mean they'll be on shelves any time soon.

Previously, Brisbane Times reported, while Ellume planned to submit its product for TGA approval early this year, the company stated it can't supply Australia with RATs until mid-2022.

However, the scramble for RATs that has likely put focus on Ellume also seems to have boosted the share price of its ASX-listed peers.

Right now, the AnteoTech Ltd (ASX: ADO) share price is up 3.92%. Meanwhile, that of Lumos Diagnostic Holdings Ltd (ASX: LDX) has gained 2.5%. Both companies are selling their RATs overseas while they await TGA clearance.

Should you invest $1,000 in Australia And New Zealand Banking Group right now?

Before you buy Australia And New Zealand Banking Group shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Australia And New Zealand Banking Group wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 3 April 2025

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

One girl leapfrogs over her friend's back.
Share Gainers

Guess which ASX All Ords stock just doubled investors' money in a month

Investors have sent the ASX All Ords stock up 100% in just one month. But why?

Read more »

two computer geeks sit across from each other with their laptop computers touching as they look confused and confounded by what they are seeing on their screens.
Share Market News

Why are a record number of retail investors buying in the dip?

Recency bias is driving retail investors to buy shares during market volatility.

Read more »

Small chocolate bunnies.
Share Gainers

Here are the top 10 ASX 200 shares today

Investors ended the short trading week on a high today.

Read more »

A male investor wearing a blue shirt looks off to the side with a miffed look on his face as the share price declines.
Share Fallers

Why Imricor, Nanosonics, Perpetual, and Tourism Holdings shares are sinking today

These shares are having a tough finish to the week. But why?

Read more »

Ecstatic man giving a fist pump in an office hallway.
Share Gainers

Why Brainchip, Challenger, Clarity, and Gorilla Gold Mines shares are storming higher

These shares are rising more than most on Thursday. But why?

Read more »

A woman sits at her computer with her chin resting on her hand as she contemplates her next potential investment.
Share Market News

Which sectors does Macquarie expect to see lower demand if there is an economic slowdown?

If you are sifting through the wasteland for opportunities and sectors to avoid, here’s what one broker has to say.

Read more »

A man holding a cup of coffee puts his thumb up and smiles while at laptop.
Broker Notes

Goldman Sachs says this ASX 200 share is dirt cheap

The broker sees big returns on the cards for buyers of this stock.

Read more »

Three people in a corporate office pour over a tablet, ready to invest.
Broker Notes

Top brokers name 3 ASX shares to buy today

Here's what brokers are recommending as buys this week.

Read more »